Myriad Genetics (MYGN) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $4.63 --0%
Revenue Growth %: -2.7%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -2.7%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.45, $0.04 better than the analyst estimate of $0.41. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $189.97 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Myriad Genetics expands Precise MRD cancer test to three tumor types
- More trouble for SpaceX? Analyst flags robotics and space as key bubble risk areas
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
